Predictive Markers Require Thorough Analytic Validation Read more about Predictive Markers Require Thorough Analytic Validation
Clinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx Read more about Clinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx
EBV–Associated Lymphoproliferative Disorders: Update in Classification Read more about EBV–Associated Lymphoproliferative Disorders: Update in Classification
The ever-changing world of gene fusions in cancer: a secondary gene fusion and progression Read more about The ever-changing world of gene fusions in cancer: a secondary gene fusion and progression
Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer Read more about Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer
Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project Read more about Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
Circulating tumor DNA analysis for patients with oncogene-addicted NSCLC with isolated central nervous system progression Read more about Circulating tumor DNA analysis for patients with oncogene-addicted NSCLC with isolated central nervous system progression
Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non–Small-Cell Lung Cancer Read more about Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non–Small-Cell Lung Cancer
Evolution of immune escape mechanisms in the progression from preinvasive to invasive human lung adenocarcinoma Read more about Evolution of immune escape mechanisms in the progression from preinvasive to invasive human lung adenocarcinoma
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial Read more about BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial